Applied Food Technologies, Inc., a growth stage biotechnology company developing molecular diagnostics to address issues related to safety, science and technology in the food industry, was the first to develop DNA based diagnostics for use in the seafood industry for species identification and verification.
Contact: LeeAnn Applewhite, CEO, 386.418.3661, firstname.lastname@example.org, appliedfoodtechnologies.com
AxoGen (OTCBB:AXGN) is a biomedical company developing products that will allow surgeons to repair and regenerate peripheral nerves more successfully than ever before.
Contact: Karen Zaderej, CEO, 386.462.6800, email@example.com, axogeninc.com
Banyan Biomarkers is developing novel biomarker diagnostic and therapeutic products to address unmet clinical needs associated with organ injury with an initial focus on traumatic brain injury.
Contact: Dr. Jackson Streeter, CEO and CMO, 386.462.6699, firstname.lastname@example.org, banyanbio.com
EigenChem Technologies, Inc. is a concept-stage start-up company developing disruptive technologies for the cleantech and biotech business sectors with a focus on novel approaches to making quantum dots for energy and biomedical applications, advanced photochemical solar cells, and turning large-scale polymeric wastes into value-added products.
Contact: Polina Oliferenko, CEO, 352.792.4008, email@example.com, eigenchem.com
MLM Biologics, Inc. is a Florida-based medical device company with concentration in regenerative medicine (musculoskeletal deficiencies) and diagnostic medicine (oncology & cardiology). The company utilizes proprietary and licensed technologies to develop, promote and distribute medical devices, primarily a biologics platform. The goal is to deliver a product portfolio that is effective both clinically (evidence and market driven) and financially (cost competitive), and have the opportunity to serve the needs of masses of patients worldwide using non-conventional marketing and sales distribution strategies.
Contact: Chandra Nataraj, President, 352.514.4269, firstname.lastname@example.org, or Ken Harvey, Vice President, 352.278.3060, email@example.com, mlmbiologics.com
Pasteuria Bioscience, Inc. a wholly-owned subsidiary of Syngenta in North America, addresses one of the world’s most important unmet pest-control challenges – parasitic nematodes which destroy plants. Using a proprietary technology platform, commercial scale in-vitro production of naturally occurring Pasteuria strains for nematode control products will benefit a wide range of crops and ornamental plants around the world.
Contact: Kelly Smith, Head, 386.518.5060,
Prevacus, Inc. is a drug development company working on prevention and treatment of mild traumatic brain injury (mTBI) or concussion. Every year 4-6 million people suffer from mTBIs many of which do not reach an emergency room and go unreported. Apart from analgesics for associated pain and anti-depressants, there are no approved pharmaceutical therapies for mTBI. Prevacus is formulating therapeutics for nasal delivery to ease use in the field and to maximize delivery to the brain. Prevasol is our flagship product. The active ingredient in Prevasol is a synthetic compound that simultaneously reduces edema, inflammation and oxidative stress.
Contact: Jake VanLandingham, CEO, 850.544.2962, firstname.lastname@example.org, prevacus.com
Prometheon Pharma, LLC develops novel transdermal delivery systems for large therapeutic biomolecules currently administered by needle injection under the skin. Prometheon’s TopiconTM platform technology offers a convenient and painless alternative to frequent injections, and provides the first drug patch with thermosensitive properties that maintain the stability of a perishable large molecule drug in a solid matrix at room temperature. Our first product line under development, TopiconTMDM, features extended-wear insulin patches that provide a conveniently dosed and needle-free alternative for insulin therapy capable of continuous and constant delivery of insulin for multiple consecutive days. Contact: Stephen I. Hsu, MD, PhD, CEO and Chief Scientific Officer, 386.418.0320, email@example.com
Zenagene, Inc. is molecular biology company focused on the development of biomarkers to predict cancer risk, in particular for those like lung and pancreatic cancer for which there is no early detection and/or clinical methods for surveillance. In addition, Zenagene is developing agents which reverse the epigenetic silencing of the anticancer gene, Brahma (BRM). Such advances are needed to enhance our pursuit of personalized medicine.
Contact: David Reisman, CEO, 734.929.7503, firstname.lastname@example.org